David N Church

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4606415/publications.pdf

Version: 2024-02-01

55	4,673	147801	182427
papers	citations	31 h-index	51 g-index

58	58	58	6739
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet, The, 2020, 395, 350-360.	13.7	364
2	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology, 2015, 28, 836-844.	5.5	343
3	DNA polymerase É› and Î´ exonuclease domain mutations in endometrial cancer. Human Molecular Genetics, 2013, 22, 2820-2828.	2.9	319
4	A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Reviews Cancer, 2016, 16, 71-81.	28.4	292
5	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	7.0	249
6	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	6.3	229
7	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
8	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	1.6	216
9	Clinicopathological and molecular characterisation of â€˜multipleâ€classifierâ€™ endometrial carcinomas. Journal of Pathology, 2020, 250, 312-322.	4.5	205
10	Interpretation of somatic POLE mutations in endometrial carcinoma. Journal of Pathology, 2020, 250, 323-335.	4.5	203
11	Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. Journal of Clinical Oncology, 2013, 31, 4297-4305.	1.6	181
12	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	3.4	141
13	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2016, 17, 1543-1557.	10.7	129
14	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 2017, 6, e1338230.	4.6	116
15	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	7.0	113
16	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	6.4	113
17	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	4.6	102
18	Survivin in Solid Tumors: Rationale for Development of Inhibitors. Current Oncology Reports, 2012, 14, 120-128.	4.0	98

#	Article	IF	Citations
19	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nature Communications, 2016, 7, 11111.	12.8	83
20	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
21	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	4.5	71
22	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology, 2016, 29, 174-181.	5.5	68
23	Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 250-254.	1.3	66
24	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data metaâ€analysis. Cancer, 2021, 127, 2409-2422.	4.1	62
25	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	8.1	60
26	Adjuvant Treatment for POLE Proofreading Domainâ€“Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. Clinical Cancer Research, 2018, 24, 3197-3203.	7.0	50
27	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open, 2020, 5, e000638.	4.5	47
28	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
29	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
30	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	6.4	41
31	Clinical review â€“ Small cell carcinoma of the bladder. Cancer Treatment Reviews, 2006, 32, 588-593.	7.7	39
32	POLE proofreading mutation, immune response and prognosis in endometrial cancer. OncoImmunology, 2016, 5, e1072675.	4.6	34
33	'Toxgnostics': an unmet need in cancer medicine. Nature Reviews Cancer, 2014, 14, 440-445.	28.4	29
34	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. Clinical Genitourinary Cancer, 2017, 15, 152-156.	1.9	25
35	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	6.2	23
36	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	1.2	21

#	Article	IF	Citations
37	What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?. Interactive Cardiovascular and Thoracic Surgery, 2014, 19, 656-660.	1.1	20
38	Vaccination of chemotherapy patientsâ€"effect of guideline implementation. Supportive Care in Cancer, 2016, 24, 2317-2321.	2.2	17
39	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 283-296.	3.0	17
40	Cancer predisposition syndromes: lessons for truly precision medicine. Journal of Pathology, 2017, 241, 226-235.	4.5	13
41	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 2021, 124, 786-796.	6.4	11
42	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. Journal of Pathology, 2022, 257, 340-351.	4.5	11
43	Changing Practice Evaluationâ€"Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocolsâ€"Experience From a Supraregional Center. Clinical Genitourinary Cancer, 2018, 16, 240-244.	1.9	8
44	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. Clinical Epigenetics, 2020, 12, 102.	4.1	8
45	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. Cancers, 2021, 13, 4538.	3.7	8
46	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective singleâ€€center clinical utility studyâ€"PRECISE study. Cancer Medicine, 2019, 8, 6305-6314.	2.8	6
47	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	4.5	6
48	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. Current Colorectal Cancer Reports, 2014, 10, 363-371.	0.5	4
49	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. EBioMedicine, 2021, 71, 103547.	6.1	4
50	Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.. Journal of Clinical Oncology, 2018, 36, 3515-3515.	1.6	4
51	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
52	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase eâ€"Mutated and Microsatellite-Instable Endometrial Cancers. JAMA Oncology, 2016, 2, 141.	7.1	2
53	A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer. Clinical Medicine Therapeutics, 2009, 1, CMT.S35.	0.1	0
54	In Reply: Response to Marioni. Current Oncology Reports, 2013, 15, 3-3.	4.0	0

#	Article	IF	Citations
55	Abstract IA015: Molecular stratification: Beyond TCGA. , 2021, , .		0